Influence of Gender on the Tolerability, Safety, and Efficacy of @entity5126 Used for Treatment of Supraventricular and XXXX .

@entity1 @entity1166 @entity5126 @entity1162 @entity943
UNASSIGNED: @entity5126 , a class IA antiarrhythmic drug (AAD), has been used for the treatment of @entity943 since the early 1900s. Use has decreased recently because of the availability of newer AADs and concerns about side effects and safety. @entity5126 can cause @entity1162 , and @entity1 have @entity1162 and are more susceptible to @entity1166 ( @entity1166 ) than are @entity1 . We sought to evaluate the influence of gender on @entity5126 tolerability, safety, and efficacy. We performed retrospective analyses of @entity1 at our institution prescribed @entity5126 as an AAD between 2000 and 2012. Time to @entity5126 discontinuation and @entity943 recurrence were evaluated using Cox proportional hazards models. In 179 @entity1 , 23.5% were @entity1 and median age was 65.8  years. @entity5126 indication was @entity943 in 68.7% and @entity943 in 27.9% of @entity1 . At 3  years after @entity5126 initiation, Kaplan-Meier probability of @entity5126 discontinuation was 65.7% for @entity1 and 82.4% for @entity1 (p  = 0.015). @entity1 were more likely than @entity1 to discontinue @entity5126 for @entity1162 (14.3 vs 4.4%, p  = 0.036) and @entity1166 (4.8 vs 0%, p  =  0.054). After multivariate adjustment, female gender remained independently associated with @entity5126 discontinuation (adjusted hazard ratio 1.97, p  = 0.014). Gender had no influence on @entity943 recurrence: 1  year after @entity5126 initiation, Kaplan-Meier probability of freedom from recurrent @entity943 was 62.4% in @entity1 and 57.9% in @entity1 (p  = 0.33). @entity5126 is highly effective in both genders. However, @entity1 are more likely than @entity1 to experience @entity1162 and @entity1166 on @entity5126 and are more likely to discontinue @entity5126 independent of these side effects.
